Formulary - A peer-reviewed drug management journalfor managed care and hospital decision-makers

FDA Approvals

Medication Safety & Reliability

Drug & Formulary Trends

Rx Technology Report

Formulary is a peer reviewed journal that provides timely, accurate, and practical drug-related information to assist our readers in their drug management responsibilities—evaluating drugs for the formulary and developing policies and procedures to guide the appropriate, rational, safe, and cost-effective use of drugs.

Coming in the May issue:

Cover story	Meeting coverage from the American College of Cardiology 61st Annual Scientific Session & Expo. Topics include: Comparison of total medical cost avoidance with the usage of new oral anticoagulants instead of warfarin among atrial fibrillation patients New use of rivaroxaban for treatment of pulmonary embolism A trial of thrombolytic therapy (alteplase) in patients with moderate pulmonary embolism
Focus on apixaban	Few Americans achieve CV health goals associated with decreased mortality.
Departments:
FDA Approvals	New molecular entity: ivacaftor (Kalydeco, Vertex Pharmaceuticals) for the treatment of cystic fibrosis in patients age 6 years and older who have a G551D mutation in the CFTR gene New formulation: extended-release exenatide (Bydureon, Amylin Pharmaceuticals) injectable suspension as a once weekly treatment (along with diet and exercise) to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.
News Capsules	Few Americans achieve CV health goals associated with decreased mortality.
Policy Watch	Expanded access to nonprescription drugs and comparative effectiveness research.

Subscribe Now! »

eNewsletter

Digital Edition

Magazine

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.